UNSPSC 51152035: Mephenesin

This classification denotes a muscle relaxant with the molecular formula C10H14O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7B8PIR2954, chemically known as 1,2-propanediol, 3-(o-tolyloxy)- but generally known as mephenesin, which bears US NIH Compound Identifier 4059. European Medicines Agency schedules Mephenesin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08746MIG. The term MEPHENESIN is an International Non-Proprietary Name.

UNSPSC 51152035 Mephenesin is a Commodity code that in recent state and local procurement records appears to capture pharmaceutical products and pharmacy-related services, though the opportunities tagged under it diverge significantly from the code's nominal scope. Seminole County, Florida recently solicited naloxone and drug deactivation systems through an IFB process, while the Texas Health and Human Services Commission issued an RFI to explore direct-to-manufacturer prescription fulfillment capabilities outside traditional pharmacy benefit manager channels. The actual buying activity under this code spans emergency-response pharmaceuticals, pharmacy benefit administration, and wholesale pharmaceutical sourcing rather than mephenesin specifically. Issuing bodies include county health departments and state health and human services agencies pursuing health-system modernization and emergency-response preparedness.

Recent opportunities show activity in Florida and Texas. Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually, posted June 30, 2026, with a response deadline of July 26, 2023, targets quarterly deliveries to the Seminole County Community Health Building in Sanford with a two-year initial term and one-year renewal option. The Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, represents an early-stage market exploration rather than a formal competitive solicitation, seeking vendor capabilities for direct-to-manufacturer prescription programs and direct contracting outside existing pharmacy benefit manager arrangements. The code shows limited recent activity and a mismatch between its nominal scope and the pharmaceutical procurement categories actually being tagged under it in the state and local market.